Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Up 12.4%

Adaptimmune Therapeutics plc (NASDAQ:ADAP) shares traded up 12.4% during mid-day trading on Friday . The stock traded as high as $1.01 and last traded at $1.01. 241,991 shares traded hands during trading, a decline of 86% from the average session volume of 1,789,893 shares. The stock had previously closed at $0.90.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on Adaptimmune Therapeutics in a research note on Friday, December 29th. They set a “hold” rating for the company.

Adaptimmune Therapeutics Stock Performance

The stock has a 50-day moving average of $1.40 and a 200 day moving average of $0.92. The firm has a market capitalization of $1.02 billion, a P/E ratio of -1.84 and a beta of 2.39.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.12). Adaptimmune Therapeutics had a negative net margin of 188.90% and a negative return on equity of 155.39%. The firm had revenue of $0.23 million during the quarter, compared to analyst estimates of $4.80 million. On average, equities analysts predict that Adaptimmune Therapeutics plc will post -0.49 EPS for the current year.

Hedge Funds Weigh In On Adaptimmune Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ADAP. Columbia Advisory Partners LLC bought a new stake in shares of Adaptimmune Therapeutics in the first quarter valued at approximately $25,000. Two Sigma Investments LP bought a new position in shares of Adaptimmune Therapeutics in the 4th quarter valued at $33,000. UBS Group AG lifted its stake in shares of Adaptimmune Therapeutics by 1,090.8% in the 4th quarter. UBS Group AG now owns 23,625 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 21,641 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Adaptimmune Therapeutics by 56.4% in the 2nd quarter. Goldman Sachs Group Inc. now owns 48,077 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 17,332 shares during the last quarter. Finally, Twin Focus Capital Partners LLC bought a new position in shares of Adaptimmune Therapeutics in the 4th quarter valued at $44,000. Institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.